Air Canada’s Stock Falls 12% On Weak Earnings And Travel Decline
Air Canada’s (AC) stock fell 12% on July 29 after the Montreal-based carrier reported weak quarterly financial results that showed a continued decline in air travel.The airline continues to see lower demand for trips to the U.S. as Canadians shy away from America, with revenue dropping 11% on 8% less capacity in this year’s second quarter. Air Canada reported earnings per share (EPS) of $0.60 for Q2, down 39% from $0.98 a year earlier.The quarterly profit fell short of the consensus expectation of analysts who had EPS of $0.72 penciled in for the company. Revenue in the April through June quarter totaled $5.03 billion, up 1% from the same period of 2024 amid tepid capacity growth.The poor results and decline in air travel demand sent AC stock down sharply. At the same time, Air Canada faces a potential labour disruption. Air Canada’s flight attendants are voting on whether to give a strike mandate to the Canadian Union of Public Employees (CUPE), which represents them in collective bargaining. The flight attendant’s vote runs until Aug. 5 of this year.Analysts say the labour unrest adds to the uncertainty that is swirling around Air Canada and its performance for the remainder of this year. AC stock is down 13% on the year and trading at $19.34 per share.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


